ZA964097B - New variant of apolipoprotein a-i - Google Patents

New variant of apolipoprotein a-i

Info

Publication number
ZA964097B
ZA964097B ZA964097A ZA964097A ZA964097B ZA 964097 B ZA964097 B ZA 964097B ZA 964097 A ZA964097 A ZA 964097A ZA 964097 A ZA964097 A ZA 964097A ZA 964097 B ZA964097 B ZA 964097B
Authority
ZA
South Africa
Prior art keywords
apolipoprotein
new variant
variant
new
Prior art date
Application number
ZA964097A
Other languages
English (en)
Inventor
Gerard Turpin
Eric Bruckert
Jean-Charles Fruchart
Gerald Luc
Patrice Denefle
Patrick Benoit
Nicolas Duverger
Gerd Assmann
Harald Funke
Original Assignee
Rhone Poulenc Rorer Sa
Pasteur Institut
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa, Pasteur Institut, Univ Paris Curie filed Critical Rhone Poulenc Rorer Sa
Publication of ZA964097B publication Critical patent/ZA964097B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
ZA964097A 1995-05-22 1996-05-22 New variant of apolipoprotein a-i ZA964097B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9506061A FR2734568B1 (fr) 1995-05-22 1995-05-22 Nouveaux variants de l'apolipoproteine

Publications (1)

Publication Number Publication Date
ZA964097B true ZA964097B (en) 1996-12-06

Family

ID=9479241

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA964097A ZA964097B (en) 1995-05-22 1996-05-22 New variant of apolipoprotein a-i

Country Status (16)

Country Link
EP (1) EP0827538A1 (ja)
JP (1) JPH11505712A (ja)
KR (1) KR19990021828A (ja)
AU (1) AU717202B2 (ja)
BR (1) BR9608813A (ja)
CA (1) CA2218759A1 (ja)
CZ (1) CZ291376B6 (ja)
FR (1) FR2734568B1 (ja)
HU (1) HUP9802926A3 (ja)
IL (1) IL118336A0 (ja)
MX (1) MX9708727A (ja)
NO (1) NO975367L (ja)
SK (1) SK156397A3 (ja)
TW (1) TW434260B (ja)
WO (1) WO1996037608A1 (ja)
ZA (1) ZA964097B (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
AU2001245622A1 (en) * 2000-03-13 2001-09-24 Amgen Inc. Apo-a-i regulation of t-cell signaling
CN1268641C (zh) 2000-11-10 2006-08-09 普罗蒂奥制药公司 载脂蛋白类似物
US8119590B2 (en) 2001-09-28 2012-02-21 Cedars-Sinai Medical Center Prevention and treatment of restenosis by local administration of drug
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
CA2486127C (en) 2002-05-17 2014-03-11 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
ES2376875T3 (es) 2003-02-14 2012-03-20 Children's Hospital & Research Center At Oakland Vehículo de administración de fármacos lipofílicos y métodos de utilización del mismo
EP1732383A4 (en) 2004-04-06 2007-05-02 Cedars Sinai Medical Center PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH VIRUS VECTORS ASSOCIATED WITH RECOMBINANT ADENOVIRUS CODING APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
WO2006012632A2 (en) * 2004-07-23 2006-02-02 Xencor, Inc. Apolipoprotein a-1 derivatives with altered immunogenicity
KR100725642B1 (ko) * 2006-01-20 2007-06-07 충남대학교산학협력단 저밀도 지단백질에 대해 항산화성을 갖는 펩타이드
MX2008015337A (es) 2006-06-01 2009-11-26 Inst Cardiologie Montreal Metodo y compuesto para el tratamiento de estenosis valvular.
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
CN102239260B (zh) * 2008-10-03 2017-04-12 库尔纳公司 通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
NZ594516A (en) 2009-02-16 2012-12-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
CN105288589A (zh) 2011-02-07 2016-02-03 塞勒尼斯医疗控股公司 脂蛋白复合物及其制备和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.

Also Published As

Publication number Publication date
NO975367D0 (no) 1997-11-21
AU717202B2 (en) 2000-03-23
AU5904896A (en) 1996-12-11
WO1996037608A1 (fr) 1996-11-28
HUP9802926A2 (hu) 1999-03-29
BR9608813A (pt) 1999-02-17
HUP9802926A3 (en) 2001-08-28
IL118336A0 (en) 1996-09-12
SK156397A3 (en) 1998-07-08
FR2734568A1 (fr) 1996-11-29
NO975367L (no) 1997-11-21
CZ291376B6 (cs) 2003-02-12
EP0827538A1 (fr) 1998-03-11
MX9708727A (es) 1997-12-31
TW434260B (en) 2001-05-16
FR2734568B1 (fr) 1997-06-20
CA2218759A1 (fr) 1996-11-28
CZ367197A3 (cs) 1998-03-18
JPH11505712A (ja) 1999-05-25
KR19990021828A (ko) 1999-03-25

Similar Documents

Publication Publication Date Title
ZA964097B (en) New variant of apolipoprotein a-i
HK1002864A1 (en) Water-dissoluble narobomycin ester
AU4237296A (en) Selective acylation of epsilon-amino groups
PL322277A1 (en) Derivatives of pyrazol-4-ylobenzoyl
GB9514437D0 (en) Inhibition of gene expression
GB9514435D0 (en) Inhibition of gene expression
PL324451A1 (en) Derivatives of diphenylmethylenepiperidine
PL319905A1 (en) Apolipoprotein b synthesis inhibitors
ZA96962B (en) Bisphenol ester derivatives
IL117668A0 (en) Preparation of polyesters
GB9718518D0 (en) Fractionation of Hemicellulosic Materials
DE69623258D1 (en) Copolyetherester
GB9507297D0 (en) New composition of matter
PL325170A1 (en) Bipolar forms of throwaflocacin
PL323148A1 (en) Esters of crabapenemes
HU9503736D0 (en) New derivatives of trans apovincaminic-acid-esters
PL323141A1 (en) Esters of crabapenemes
GB9513043D0 (en) Selection of recombinant molecules
SG64924A1 (en) Inhibiting photodecompostion of 3-substituted-2- oxindoles
KR0110698Y1 (en) Suspension of autoseat
HU9502606D0 (en) New intermediers of ace-inhibitors
GB9504379D0 (en) Fractionation of mixtures
ZA962440B (en) Destressing of railtracks
GB2316947B (en) Selection of recombinant molecules
GB9525144D0 (en) Purification of esters